These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 25397538)

  • 41. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
    Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V; Allavena C; François-Brunet C; Perré P; Bellein V; Garré M; May T; Souala F; Besnier JM; Raffi F
    HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study.
    Portilla J; Arazo P; Crusells J; Pérez-Martínez L; Martínez-Madrid O; Boix V; Moreno J; Navarro V; Rubio T; Reus S; Galera C; Bernal E; Jover F; Amador C; Baño D; Merino E; Saiz-de-la-Hoya P
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19803. PubMed ID: 25397547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA.
    Bianco C; Meini G; Rossetti B; Lamonica S; Mondi A; Belmonti S; Fanti L; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19791. PubMed ID: 25397535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years.
    Podzamczer D; Tiraboschi JM; Mallolas J; Curto J; Cárdenes MA; Casas E; Castro A; Echevarría S; Leal M; Lopez Bernaldo de Quirós JC; Moreno S; Puig T; Ribera E; Villalonga C; Gómez-Sirvent JL; García-Henarejos JA; Lopez-Aldeguer J; Barrufet P; Force L; Santos I; Sanz J
    Curr HIV Res; 2012 Sep; 10(6):513-20. PubMed ID: 22716109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study.
    Carrero-Gras A; Antela A; Muñoz-Rodríguez J; Díaz-Menéndez M; Viciana P; Torrella-Domingo A; Sanz-Moreno J; Téllez-Molina MJ; Moreno J; Hernández-Quero J; Pérez-Hernández IA; Domingo-Pedrol P
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19819. PubMed ID: 25397563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of the nevirapine safety signal using data from the national antiretroviral dispensing database: a retrospective study.
    Kalemeera F; Mengistu AT; Gaeseb J
    J Pharm Policy Pract; 2016; 9():5. PubMed ID: 26881055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiretroviral therapy hepatotoxicity: Prevalence, risk factors, and clinical characteristics in a cohort of Han Chinese.
    Gao S; Gui XE; Deng L; Zhang Y; Liang K; Yang R; Yan Y; Rong Y
    Hepatol Res; 2010 Apr; 40(4):287-94. PubMed ID: 20070390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: in settings of low CD4 cell counts and resource limitation.
    Kiertiburanakul S; Sungkanuparph S; Malathum K; Watcharananan S; Sathapatayavongs B; Charoenyingwattana A; Mahasirimongkol S; Chantratita W
    Open AIDS J; 2009 Jul; 3():24-30. PubMed ID: 19639037
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study.
    Elías MJ; Arroyo D; Diaz A; Herrero C; Martinez-Dueñas L; Moreno A; Hernández-Quero J; Podzamcer D; Gomez-Ayerbe C; Casado JL; Zamora J; Rivero A; Moreno S; Llibre JM
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19800. PubMed ID: 25397544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis.
    Mazzitelli M; Trunfio M; Putaggio C; Sasset L; Leoni D; Lo Menzo S; Mengato D; Cattelan AM
    Biomedicines; 2022 Jul; 10(8):. PubMed ID: 36009370
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Who gets single tablet regimens (STR), and why?
    Tarrier L; Kegg S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19777. PubMed ID: 25397521
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A characterization of the HIV population with limited/exhausted treatment options: a multicenter Belgian study.
    Nasreddine R; Darcis G; Yombi JC; De Munter P; Florence E; Van Praet J; Demeester R; Allard SD; Schroeder M; Dusabineza AC; Delforge M; De Wit S
    Acta Clin Belg; 2024 May; ():1-7. PubMed ID: 38813800
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Motor lumbosacral radiculopathy in HIV-infected patients.
    Moodley K; Bill PLA; Patel VB
    South Afr J HIV Med; 2019; 20(1):992. PubMed ID: 31745432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changing incidence of nevirapine-induced cutaneous drug reactions: After revised guideline Nov 2011.
    Lokhande AJ; Sutaria A; Shah BJ; Shah AN
    Indian J Sex Transm Dis AIDS; 2013 Jul; 34(2):113-8. PubMed ID: 24339462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical perspectives on human genetic screening to prevent nevirapine toxicity.
    Haas DW; Mootsikapun P; Ruxrungtham K; Podzamczer D;
    Per Med; 2012 Sep; 9(7):773-782. PubMed ID: 23439719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CD4 Cell Count: Declining Value for Antiretroviral Therapy Eligibility.
    Ying R; Granich RM; Gupta S; Williams BG
    Clin Infect Dis; 2016 Apr; 62(8):1022-8. PubMed ID: 26826372
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity.
    Patterson P; Socías E; Pryluka D; Lapadula P; Pérez H; Cahn P
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19794. PubMed ID: 25397538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
    Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
    Pinnetti C; Di Giambenedetto S; Maggiolo F; Lorenzini P; Fabbiani M; Tommasi C; Latini A; Ammassari A; Loiacono L; Sterrantino G; Bellagamba R; Boumis E; Antinori A; Zaccarelli M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19812. PubMed ID: 25397556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.